Original Forxiga’s sales strong despite generic entry

Prescription of original Forxiga and Xigduo surge

Forxiga’s sales rise 15%, Xigduo 10%... Succeeds in defending prescription performance amid the inflow of many generics

62 single-agent generics and 32 combination generics released... prescriptions per company less than KRW 100 million

Pic of Forxiga (left)·Xigduo

Three months have passed since generic versions of the SGLT-2 inhibitor class diabetes treatment ‘Forxiga (dapaglifloin)’ were released en masse in Korea.

 

Despite the release, the original product had successfully defended its lead, increasing outpatient prescriptions.

 

The generic companies raised a combined prescription performance of KRW 5.9 billion in the first quarter after their release, increasing their influence to 18% of the total market.

 

However, as more than 60 companies that have entered the competition, the average prescription performance per company was less than KRW 100 million.

 

Despite entry of a large number of generics...Prescriptions of Forxiga, Xigduo rise 12% within the year On the 22nd, according to the market research institution UBIST, the outpatient prescriptions of single agent and combination dapagliflozin drugs in Q2 was KRW 32.2 billion.

 

Among those, Forxiga and Xigduo posted combined sales of KRW 26.3 billion.

 

Compared to the KRW 23.4 billion in Q2 last year, the sales of the two drugs rose 12% YoY.

 

Generic drugs entered in bulk after Foxiga’s substance patent expired in April.

 

Over 60 companies have released Xigduo generics in Q2 alone.

 

The generic companies posted combined prescriptions of KRW 5.9 billion in Q2.

 

Its share in the overall market increased to 18% in 3 months.

 

Despite the increasing performance of generic drugs in the market, prescriptions of Forxiga and Xigduo have increased.

 

Industry analysis that AstraZeneca is defending its performance by carrying out active promotion activities with its copromotion partner, Daewoong Pharmaceutical.

 

Forxiga and Xigduo’s drug prices were not reduced despite the release of generics.

 

Originally, the drug prices of Forxiga and Xigduo were scheduled to be reduced by 30% ex offico by the Ministry of Health and Welfare following the reimbursement listing of its same ingredient generics.

 

However, AstraZeneca filed an administrative suit claiming that the disposition was unfair and requested that the disposition be delayed until the ruling is complete.

 

The court cited the request for suspension of execution, and the drug prices of Forxiga and Xigduo had remained the same ever since.

 

Combined prescription of generic drugs amount to KRW 5.9 billion...Average sales per generic company less than KRW 100 million As for the generic companies, each company produced less than KRW 100 million per company.

 

So many companies have simultaneously released their generic versions that the prescriptions each company had made were at an insignificant level.

 

In Q2, 62 companies had released their single-agent Forxiga generic drugs, raising KRW 3.9 billion in total.

 

Each company made roughly KRW 62 million.

 

Only 5 of the companies’ products - Boryung’s Trudapa, Hanmi Pharm’s Dapalon, Chong Kun Dang’s Exiglu, Aju Pharm’s Daparil, Dong-A ST’s Dapapro – made over KRW 200 million in Q2.

 

50 of the 62 companies (81%) that released their generic versions had made less than KRW 100 million in Q2.

 

The situation was similar for the combination generic drugs as well.

 

32 companies had released their generic Xigduo versions and posted combined sales of KRW 2.1 billion.

 

Each company made roughly KRW 65 million.

 

Only 5 of the companies’ products - Hanmi Pharm’s Dapalon Duo, Boryung’s Trudapa M, Kyung Dong Pharma’s Dapamet SR, Daewon Pharmaceutical’s Dapawon-M, Aju Pharm’s Daparil Duo - made over KRW 200 million in Q2.

 

25 of the 32 companies (78%) that released their generic versions had made less than KRW 100 million in Q2.